Skip to content
OpenCapital
Get started

Bausch + Lomb BLCO Pharmaceuticals — R&D

Other segment segments

Surgical
$13M+18.2%
Vision Care
$10M+25.0%

Similar metrics at other companies

Abbott logo
ABTEstablished Pharmaceuticals — R&D
$41M-2.4%
Baxter International logo
BAXPharmaceuticals — Research and development expenses
$22M-15.4%
Vertex Pharmaceuticals logo
VRTXPharmaceuticals — Research expenses
$205M-0.5%
BioMarin Pharmaceuticals logo
BMRNResearch and early pipeline — R&D
$87.29M-3.5%
United Therapeutics logo
UTHRR&D
$138.2M-7.2%
Glaukos logo
GKOSDevelopment And Commercialization Of Ophthalmic Therapies — Research And Development Expense
$28.97M+26.4%

Other financials

Income statement

See full
Revenue$1.2B+9.4%
Operating income$33.0M+140%
Net income-$71.0M+66.5%
EPS (diluted)-$0.20+66.7%

Balance sheet

See full
Cash & equivalents$279.0M+29.8%
Total debt$5.0B+4.3%
Total equity$6.4B+0.3%
Total assets$13.8B+2.6%

Cash flow

See full
Operating cash flow$32.0M+228%
CapEx$100.0M-9.1%
Free cash flow-$68.0M+49.6%

Valuation

See full
Market cap$5.43B+10.2%

Profitability

See full
Operating margin4.4%+2.9pp
Net margin-4.2%-1.3pp
FCF margin-3.4%0.0pp

Returns & leverage

See full
Return on equity-3.4%-0.9pp
Debt / equity0.8×0.0×
Current ratio1.5×0.0×

Where this comes from

Reported directly by Bausch + Lomb in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Bausch + Lomb’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch + Lomb's pharmaceuticals — r&d.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bausch + Lomb's pharmaceuticals — R&D?
Bausch + Lomb (BLCO) reported pharmaceuticals — R&D of $22M in Q1 2026.
How has Bausch + Lomb's pharmaceuticals — R&D changed year-over-year?
Bausch + Lomb's pharmaceuticals — R&D increased by 144.4% year-over-year, from $9M to $22M.
What is the long-term trend for Bausch + Lomb's pharmaceuticals — R&D?
Over 3 years (2022 to 2025), Bausch + Lomb's pharmaceuticals — R&D has grown at a 22.3% compound annual growth rate (CAGR), from $29M to $53M.
What does pharmaceuticals — R&D mean?
Tracks the investment in scientific discovery, clinical trials, and regulatory processes required to bring new ophthalmic pharmaceutical products to market. This metric is a critical proxy for the segment's long-term innovation pipeline and future competitive positioning.